POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes

Chest

Volumn 150, Issue 2, 2016, Pages 273-275

  King, Christopher S ^a   Nathan, Steven D ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; NINTEDANIB; PIRFENIDONE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE; TUMOR NECROSIS FACTOR;

DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EDITORIAL; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG DIFFUSION CAPACITY; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); DECISION MAKING; SEVERITY OF ILLNESS INDEX;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; DECISION MAKING; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PYRIDONES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84981294590     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.04.034     Document Type: Editorial

References (15)

1. 1 Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu, G., Anstrom, K.J., et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366 (2012), 1968–1977.
2. 2 Noth, I., Anstrom, K.J., Calvert, S.B., et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186 (2012), 88–95.
3. 3 Nathan, S.D., Meyer, K.C., IPF clinical trial design and endpoints. Curr Opin Pulm Med 20 (2014), 463–471.
4. 4 Karimi-Shah, B.A., Chowdhury, B.A., Forced vital capacity in idiopathic pulmonary fibrosis—FDA review of pirfenidone and nintedanib. N Engl J Med 372 (2015), 1189–1191.
5. 5 Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
6. 6 Noble, P.W., Albera, C., Bradford, W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377 (2011), 1760–1769.
7. 7 King, T.E. Jr., Bradford, W.Z., Castro-Bernardini, S., et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2083–2092.
8. 8 Richeldi, L., du Bois, R.M., Raghu, G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082.
9. 9 Ley, B., Ryerson, C.J., Vittinghoff, E., et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156 (2012), 684–691.
10. 10 Harari, S., Caminati, A., Albera, C., et al. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. Respir Med 109 (2015), 904–913.
11. 11 Kolb, M., Richeldi, L., Kimura, T., et al. Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: Results from the INPULSIS trials. Am J Respir Crit Care Med, 191, 2015, A1021.
12. 12 Albera, C., Bradford, W.Z., Costabel, U., et al. Pirfenidone is efficacious in patients with idiopathic pulmonary fibrosis (IPF) and mild or more pronounced physiological impairment. Am J Respir Crit Care Med, 191, 2015, A1018.
13. 13 Nathan, S.D., Shlobin, O.A., Weir, N., et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 140 (2011), 221–229.
14. 14 Cottin, V., Maher, T., Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev 24 (2015), 58–64.
15. 15 Crestani, B., Ogura, M., Pelling, K., et al. Safety and Tolerability of nintedanib in patients with IPF: interim analysis from an open-label extension of the Inpulsis trials (Inpulsis-On). Am J Respir Crit Care Med, 191, 2015, A1020.